Stoke Therapeutics, Inc. STOK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$50M-144% | -$57.93M-453% | -$38.35M-45.1% | -$23.48M+8.6% | $112.88M+528% | ||
| $439K-8.0% | $405K-23.0% | $442K-18.1% | $446K-18.6% | $477K-15.3% | ||
| $8.75M+29.6% | $9.85M+37.9% | $8.04M+7.3% | $7.6M+2.3% | $6.75M+24.8% | ||
| -$1.49M-212% | —— | —— | —— | $1.33M+10,500% | ||
| $3.59M+192% | —— | —— | $5.18M+704% | $1.23M+252% | ||
| -$2.19M-123% | —— | -$4.06M-31.2% | -$10.04M-239% | $9.43M+489% | ||
| -$60.58M-146% | —— | —— | —— | $131.83M+637% | ||
| $353K+132% | $232K+452% | $132K+28.2% | $154K+235% | $152K+1,167% | ||
| $50.69M+272% | -$61.06M— | $0+100% | -$148.48M-68.2% | $13.63M+36.5% | ||
| $3.21M+219% | $4.56M+704% | $2.49M+1,690% | $554K-27.7% | $1M+302% | ||
| $84.33M+6,037% | $92.34M+16,157% | $3.12M-61.8% | $554K-99.5% | $1.37M-20.0% | ||
| $74.44M-49.3% | $0+100% | -$18.15M+58.2% | -$173.35M-1,264% | $146.83M+1,242% | ||
| $439K-8.0% | $405K-23.0% | $442K-18.1% | $446K-18.6% | $477K-15.3% | ||
| -$15.72M-432% | $8.9M+309% | $4.88M— | $2.77M-22.7% | $4.74M+347% | ||
| -$2.19M-123% | —— | -$4.06M-31.2% | -$10.04M-239% | $9.43M+489% | ||
| $3.59M+192% | —— | —— | $5.18M+704% | $1.23M+252% | ||
| $608K+1.5% | $650K+11.7% | $547K-4.2% | $612K+8.9% | $599K+8.9% | ||
| —— | $21.95M+880% | $21.95M+880% | $21.95M+880% | $21.95M+880% | ||
| $80.66M— | —— | —— | —— | $0-100% | ||
| $465K+25.7% | —— | $632K+73.6% | —— | $370K+120% | ||
| $334K+1,137% | $390K+680% | $41K+273% | $24K+500% | $27K+350% | ||
| -$60.94M-146% | —— | —— | —— | $131.68M+636% | ||
| -$60.94M-146% | —— | —— | —— | $131.68M+636% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Stoke Therapeutics, Inc. generate?
- Stoke Therapeutics, Inc. (STOK) generated $26.4M in operating cash flow over the trailing twelve months.
- What is Stoke Therapeutics, Inc.'s free cash flow?
- After $871.0K of capital expenditures, Stoke Therapeutics, Inc.'s free cash flow was $25.8M over the trailing twelve months, up 132.0% year over year.
- Where does Stoke Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
